Familial hypercholesterolemia treated by plasma exchange and immunoadsorption

IA clearly improved JL's HDL and LDL/HDL ratio because of its specificity, yet the extent of TC and LDL reduction per treatment was not as high as that obtained with TPE. Studies to achieve more efficient and specific extracorporeal lipid removal are in progress to help reduce the risk of CAD in FH patients and others. The continuity of procedural care and supportive needs provided by the nephrology nurses demonstrated a positive influence on J.L.'s acceptance of his familial genetic disorder and the prescribed chronic treatment regimen.